Incyte (INCY) Long-Term Deferred Tax (2017 - 2026)
Incyte's (INCY) quarterly Long-Term Deferred Tax came in at $336.9 million in Q2 2026, down 48.36% YoY from $652.3 million in Q2 2025, and down 25.56% on a QoQ basis from $452.5 million in Q1 2026.
Incyte (INCY) Long-Term Deferred Tax (2017 - 2026) Analysis & Trends
Incyte (INCY) has 10 years of Long-Term Deferred Tax data on file, last reported at $336.9 million in Q2 2026.
- Quarterly Long-Term Deferred Tax fell 48.36% year-over-year to $336.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $336.9 million (down 48.36% YoY) and the FY2025 annual result came in at $515.3 million, down 32.38% from the prior year.
- Long-Term Deferred Tax fell to $336.9 million in Q2 2026, from $452.5 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $768.9 million in Q1 2025 to a low of $336.9 million in Q2 2026.
- A 5-year average of $565.7 million and a median of $530.3 million in 2023 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax soared 37.98% — and 2026, when it plunged 48.36%.
- Tracing INCY's Long-Term Deferred Tax over 5 years: stood at $457.9 million in 2022, then soared by 37.98% to $631.9 million in 2023, then advanced by 20.6% to $762.1 million in 2024, then tumbled by 32.38% to $515.3 million in 2025, then plunged by 34.63% to $336.9 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $336.9 million (Q2 2026), $452.5 million (Q1 2026), and $515.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 336.86 Mn |
| Mar 31, 2026 | 452.52 Mn |
| Dec 31, 2025 | 515.29 Mn |
| Sep 30, 2025 | 528.14 Mn |
| Jun 30, 2025 | 652.28 Mn |
| Mar 31, 2025 | 768.90 Mn |
| Dec 31, 2024 | 762.07 Mn |
| Sep 30, 2024 | 762.31 Mn |
| Jun 30, 2024 | 729.56 Mn |
| Mar 31, 2024 | 666.57 Mn |
| Dec 31, 2023 | 631.89 Mn |
| Sep 30, 2023 | 564.39 Mn |
| Jun 30, 2023 | 532.51 Mn |
| Mar 31, 2023 | 494.75 Mn |
| Dec 31, 2022 | 457.94 Mn |
| Sep 30, 2022 | 426.84 Mn |
| Jun 30, 2022 | 434.87 Mn |
| Mar 31, 2022 | 465.37 Mn |
| Dec 31, 2021 | 467.54 Mn |
| Dec 31, 2020 | 2.05 Mn |